Literature DB >> 11501512

The impact of psoriasis on quality of life.

L H de Arruda1, A P De Moraes.   

Abstract

Psoriasis is a chronic inflammatory skin disease in which the signs vary from one patient to another and over time. Traditionally, physicians have used various parameters to assess the severity of the disease: percentage of body surface area covered, erythema, plaque thickness, degree of scaling and systemic symptoms such as arthritis. However, these clinical assessments alone do not accurately reflect the overall effect of the disease on patients' daily activities. Apart from the clinical severity of affected areas, psoriasis can also have a profound psychosocial impact on the patient's quality of life. This concept is multidimensional, encompassing the physical, social and psychological wellbeing of the person and is based on the patient's view of their condition.

Entities:  

Mesh:

Year:  2001        PMID: 11501512     DOI: 10.1046/j.1365-2133.2001.144s58033.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

1.  Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool.

Authors:  Ivan Grozdev; Douglas Kast; Lauren Cao; Diana Carlson; Prasad Pujari; Brian Schmotzer; Denise Babineau; Elizabeth Kern; Thomas McCormick; Kevin D Cooper; Neil J Korman
Journal:  J Invest Dermatol       Date:  2011-12-29       Impact factor: 8.551

Review 2.  Application of the dermatology life quality index in clinical trials of biologics for psoriasis.

Authors:  Mohammad Khurshid Azam Basra; Sadath Hussain
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

3.  Cognitive load and emotional processing in psoriasis: a thermal imaging study.

Authors:  Maria Serena Panasiti; Giorgia Ponsi; Bianca Monachesi; Luigi Lorenzini; Vincenzo Panasiti; Salvatore Maria Aglioti
Journal:  Exp Brain Res       Date:  2018-10-29       Impact factor: 1.972

4.  Physiological and behavioral reactivity to social exclusion: a functional infrared thermal imaging study in patients with psoriasis.

Authors:  Giorgia Ponsi; Bianca Monachesi; Vincenzo Panasiti; Salvatore Maria Aglioti; Maria Serena Panasiti
Journal:  J Neurophysiol       Date:  2018-10-31       Impact factor: 2.714

5.  Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Authors:  Richard G B Langley; Kristian Reich; Vibeke Strand; Steven R Feldman; Carle Paul; Kenneth Gordon; Richard B Warren; Darryl Toth; Enkeleida Nikaï; Baojin Zhu; Orin Goldblum; Emily Edson-Heredia; Hilde Carlier; Russel Burge; Chen-Yen Lin; Kristin Hollister; Matthias Augustin
Journal:  Qual Life Res       Date:  2019-10-26       Impact factor: 4.147

6.  Emerging treatments in the management of psoriasis: biological targeting with ustekinumab.

Authors:  Marina Papoutsaki; Antonio Costanzo; Sergio Chimenti
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-05-22

7.  Quality of life in patients with psoriasis.

Authors:  Monali J Bhosle; Amit Kulkarni; Steven R Feldman; Rajesh Balkrishnan
Journal:  Health Qual Life Outcomes       Date:  2006-06-06       Impact factor: 3.186

8.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Authors:  Richard Shikiar; Mary Kaye Willian; Martin M Okun; Christine S Thompson; Dennis A Revicki
Journal:  Health Qual Life Outcomes       Date:  2006-09-27       Impact factor: 3.186

9.  Nail psoriasis as a severity indicator: results from the PsoReal study.

Authors:  Marc A Radtke; Anna K Langenbruch; Ines Schäfer; Katharina Herberger; Kristian Reich; Matthias Augustin
Journal:  Patient Relat Outcome Meas       Date:  2010-12-22

10.  Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

Authors:  Dennis A Revicki; Alan Menter; Steven Feldman; Miriam Kimel; Neesha Harnam; Mary K Willian
Journal:  Health Qual Life Outcomes       Date:  2008-10-02       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.